Induction of cytotoxic lymphocyte response to hepatitis C virus using anthrax toxin-mediated antigen delivery system
Induction of cytotoxic lymphocyte response to hepatitis C virus using anthrax toxin-mediated antigen delivery system
批准号:
11670303
负责人:
MORIYA Osamu
金额:
$1.79万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We have investigated the protective antigen (PA) and recombinant lethal factor (LF) expressing epitope of hepatitis C virus (HCV) to induce cytotoxic T lymphocytes (CTL). Fusion protein of LF with epitope of core region (LMGYIPLVGA : #1) induced CTL response comparable with recombinant plasmid DNA encoding the core epitope when immuinzed mice with PA.In addition to #1 epitope, CTL activity was detected in another core epitope (YLLPRRGPRL : #5). These results indicate that antigen delivery system of PALF may be useful as HCV vaccine candidate. In the route screening for immunization among the intramuscle, subcutis and intraperitoneum, intra- muscular route seems to be better. To compare the immunization condition between the J774 A.1, macrophage cell line, pulsed with PALF#1 ex vivo and conventional solution of PALF#1, strong- er CTL response was obtained in the former immunization protocol. When compared the antigen presenting cells, dendritic cells was more efficient to elicite CTL response than the application by J774 A.1. Immunization with PA and LF#1 adsorbed to latex beads elicited strong CTL response. When latex beads were treated with PALF#l together with anti-CD40 and GM-CSF, CTL response was at least 2-fold more efficiently than was PALF#1 latex beads. CTL induced by PALF#1 could kill the targets expressed the epitope endo- geneously after infection of recombinant vaccinia virus expressing core protein. These findings are indicating that application of PA and LF-epitope is an efficient molecular tool to use as CTL vaccine. The findings of this antigen delivery system may give us some useful informations for new approach concerning HCV vaccine development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New therapeutic vaccines by using small membrane vesicle secreted by dendritic cells: New development for chronic virus infections
-
批准号:22591111
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2010
-
负责人:MORIYA Osamu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
FGF21通过CTL1介导的胆碱稳态调控线粒体自噬对帕金森病的保护机制研究
-
批准号:MS25H310003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:李晨
-
依托单位:
S1P诱导LSEC分泌IL-12调控HBV特异性CTL应答的机制及作为HBeAg阴性慢性乙型肝炎急性发作分型标志物的研究
-
批准号:2025JJ50652
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:吴伟民
-
依托单位:
CD4+ CTL通过杀伤抗原呈递细胞减轻放射性脑损伤的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:石中山
-
依托单位:
E3泛素连接酶Ctl-b通过DBC1/SIRT1轴调控小胶质细胞NLRP3炎性小体在老年PND中的作用及机制研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:陈勇
-
依托单位:
AuNPs@CTLA-4/Nb16-Fc多臂纳米抗体增强DC/肿瘤融合疫苗诱导特异性CTL抗癌研究
-
批准号:82360559
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2023
-
负责人:刘爱群
-
依托单位:
肿瘤细胞微颗粒诱导肥大细胞活化介导CTL细胞耗竭促恶性胸腔积液进展的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:
-
依托单位:
CTCFL调控IL-10抑制CD4+CTL旁观者激活促口腔鳞状细胞癌新辅助免疫治疗抵抗机制研究
-
批准号:82373325
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:夏荣辉
-
依托单位:
肿瘤细胞TMEM87a介导CTL杀伤抵抗的机制研究
-
批准号:82302075
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:李经
-
依托单位:
恶性胸腔积液肿瘤细胞微颗粒中干细胞因子刺激肥大细胞脱颗粒介导CTL细胞耗竭的作用及机制研究
-
批准号:--
-
项目类别:--
-
资助金额:30万元
-
批准年份:2023
-
负责人:张帅
-
依托单位:
具备CTL增强效应的IBV优势表位对清除变异株的作用及机制研究
-
批准号:32302906
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:夏静
-
依托单位: